Compare Accenture plc (ACN) vs Revvity Inc (RVTY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Accenture plc vs Revvity Inc — how do they compare? Accenture plc trades at $138.95 (market cap $86.98B), while Revvity Inc trades at $108.81 (market cap $12.50B). The key difference: Accenture plc is far larger — about 7× Revvity Inc's market cap, and Accenture plc pays the higher dividend (4.59%). Which is the better fit depends on your goals.
| ACN | RVTY | |
|---|---|---|
Market Cap | $86.98B | $12.50B |
Sector | Technology | Technology |
52-Week High | $303.33 | $117.75 |
52-Week Low | $124.41 | $82.26 |
Enterprise Value | $85.20B | $14.99B |
Dividend Yield | 4.59% | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Accenture (ACN) trades at $136.96, down 0.28% on the day, with technical indicators showing a bearish bias despite recent earnings beats. The company reported strong revenue growth to $69.67B in 2025 with a net margin of 10.66%, supported by strategic AI partnerships announced in June 2026. Valuation ratios appear attractive with a P/E of 10.94 and EV/EBITDA of 6.65, while analyst consensus remains strongly bullish with a $193.92 price target.
The outlook is positive given consistent earnings outperformance, expanding AI-driven consulting partnerships, and solid cash flow generation. Key risks include competitive pressures in consulting services, execution challenges in integrating AI initiatives, and potential macroeconomic headwinds affecting client spending. The stock offers fundamental value with growth catalysts from digital transformation demand.
Revvity (RVTY) trades at $112.95, down 0.71% on the day, with strong technical momentum indicated by bullish moving averages. The company has consistently beaten earnings estimates for three consecutive quarters, with Q2 2026 results pending. Recent AI integration announcements with Anthropic's Claude platform highlight ongoing innovation in scientific R&D workflows.
The stock presents a mixed outlook with strong earnings performance and AI-driven growth initiatives offset by elevated valuation multiples. Key risks include margin pressure and competitive threats in the life sciences sector. Analyst consensus leans bullish with a $109.38 price target, though current price exceeds this level.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Accenture plc
Accenture PLC provides management and technology consulting services and solutions. The Company delivers a range of specialized capabilities and solutions to clients across all industries on a worldwide basis. Accenture operates a network of businesses provides consulting, technology, outsourcing, and alliances.
Read more on ACN →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
